81 related articles for article (PubMed ID: 28635318)
21. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
Chan KH; Zengerle M; Testa A; Ciulli A
J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
[TBL] [Abstract][Full Text] [Related]
22. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
24. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
[TBL] [Abstract][Full Text] [Related]
25. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
[TBL] [Abstract][Full Text] [Related]
26. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
28. The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
Wollebo HS; Bellizzi A; Cossari DH; Salkind J; Safak M; White MK
J Neurovirol; 2016 Oct; 22(5):615-625. PubMed ID: 27007123
[TBL] [Abstract][Full Text] [Related]
29. BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.
Bhagwat AS; Roe JS; Mok BYL; Hohmann AF; Shi J; Vakoc CR
Cell Rep; 2016 Apr; 15(3):519-530. PubMed ID: 27068464
[TBL] [Abstract][Full Text] [Related]
30. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
31. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Winter GE; Buckley DL; Paulk J; Roberts JM; Souza A; Dhe-Paganon S; Bradner JE
Science; 2015 Jun; 348(6241):1376-81. PubMed ID: 25999370
[TBL] [Abstract][Full Text] [Related]
32. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
[TBL] [Abstract][Full Text] [Related]
33. A Bead-Based Proximity Assay for BRD4 Ligand Discovery.
Roberts JM; Bradner JE
Curr Protoc Chem Biol; 2015 Dec; 7(4):263-278. PubMed ID: 26629616
[TBL] [Abstract][Full Text] [Related]
34. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
Devaraj SG; Fiskus W; Shah B; Qi J; Sun B; Iyer SP; Sharma S; Bradner JE; Bhalla KN
Leukemia; 2016 Feb; 30(2):504-8. PubMed ID: 26148704
[No Abstract] [Full Text] [Related]
35. Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
Borysko P; Moroz YS; Vasylchenko OV; Hurmach VV; Starodubtseva A; Stefanishena N; Nesteruk K; Zozulya S; Kondratov IS; Grygorenko OO
Bioorg Med Chem; 2018 Jul; 26(12):3399-3405. PubMed ID: 29764756
[TBL] [Abstract][Full Text] [Related]
36. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
37. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
38. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
39. Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.
Zhang QG; Qian J; Zhu YC
Immunol Lett; 2015 Aug; 166(2):103-8. PubMed ID: 26093279
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.
Vidler LR; Filippakopoulos P; Fedorov O; Picaud S; Martin S; Tomsett M; Woodward H; Brown N; Knapp S; Hoelder S
J Med Chem; 2013 Oct; 56(20):8073-88. PubMed ID: 24090311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
